低分子肝素钠治疗胎儿生长受限的临床研究

Clinical Study of Low Molecular Weight Heparin in Treatment of Fetal Growth Restriction

目的探讨低分子肝素钠治疗胎儿生长受限的临床效果及安全性。方法选择56例FGR孕妇随机分为A组和B组各28例,A组给予低分子肝素钠治疗,B组给予低分子右旋糖酐加丹参治疗,对合并有子痫前期的孕妇同时给予解痉降压治疗。结果 A组与B组在宫高、胎儿双顶径、股骨长、头围腹围、脐血流S/D值、羊水指数改变、胎儿生物物理评分、新生儿体重和新生儿窒息率的比较差异均有统计学意义(P<0.05);两组治疗前后血小板计数和凝血功能指标进行比较,差异无统计学意义(P>0.05)。结论低分子肝素钠有助于改善FGR孕妇的治疗效果,且对母亲和胎儿安全性均较好。

Objective To evaluate the clinical efficacy and safety of low molecular weight heparin in treatment of fetal growth restriction. Methods All 56 pregnant women with FGR were randomly divided into group A and group B, with 28 cases in each. Group A received low molecular weight heparin, and group B received low molecular weight dextran Salvia mihiorrhiza treatment. The pregnant women with preeclampsia were given antispasmodic and antihypertensive treatment. Results The height of the uterus, fetal biparietal diameter, femur length, head circumference, abdominal circumference, umbilical S/D values, changes in the amniotic fluid index, fetal biophysical score, birth weight, neonatal asphyxia of group A and group B were different （ P 〈 0.05 ）. Platelet count and coagulation parameters of before and after treatment were not significant different （ P 〉 0.05 ）. Conclusion The low molecular weight heparin helps to improve outcomes of patients with FGR. The low molecular weight heparin has good safety for the mother and fetus.